Panbela Therapeutics (PBLA)

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. isdedicated to treating patients with pancreatic cancer and exploring SBP-101's potential for efficacy in combination with other agents and in treating other types of cancer.

Company profile

Ticker

PBLA

Exchange

NASDAQ

Website

panbela.com

CEO

Michael Cullen

Incorporated

Delaware

Location

Minnesota

Fiscal year end

Dec 31

Sector

Professional, Scientific, and Technical Services > Computer Systems Design Services

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...

Former names

Cimarron Medical, Inc., CIMARRON SOFTWARE INC, Sun BioPharma, Inc.

SEC CIK

0001029125

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Canary Merger Holdings, Inc. • Panbela Therapeutics Pty Ltd ...

PBLA stock data

1M 1Y 5Y

News

From Benzinga Pro

Panbela Announces First Patient Enrolled In Aspire Trial Studying SBP-101 In Combination With Gemcitabine, Nab-Paclitaxel In Patients With Metastatic Pancreatic Ductal Adenocarcinoma

11 Aug 22

Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has enrolled the first patient in

Panbela Expands Aspire Trial To Australia, Studying SBP-101 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Ductal Adenocarcinoma

4 Aug 22

This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday

25 Jul 22

Gainers

This Consumer Defensive Stock Is Trading Higher By Around 49%, Here Are 46 Stocks Moving In Friday's Mid-Day Session

22 Jul 22

Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday

6 Jul 22

Press releases

From Benzinga Pro

Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial Results

1 Aug 22

MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today

Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic

28 Jun 22

In vitro studies determined that SBP-101 reduced cellular viability across a broad range of cancer cell types, with an exceptionally strong reduction in ovarian adenocarcinoma viability resulting in a 42% increase in

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

12 May 22

12 Aug 22

31 Dec 22

Financial summary

Financial statements Chart PBLA financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	7.39M	7.39M	7.39M	7.39M	7.39M	7.39M
Cash burn (monthly)	1.49M	59.33K	1.33M	1.01M	1.49M	768.5K
Cash used (since last report)	6.6M	262.07K	5.9M	4.45M	6.6M	3.39M
Cash remaining	788.49K	7.12M	1.49M	2.94M	785.55K	3.99M
Runway (months of cash)	0.5	120.1	1.1	2.9	0.5	5.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

PBLA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
13 Sep 21	Horvath Susan	Employee Stock Option Common Stock	Grant	Acquire A	No	No	2.26	12,135	27.43K	12,135
13 Sep 21	Simpson Jennifer K.	Employee Stock Option Common Stock	Grant	Acquire A	No	No	2.26	19,125	43.22K	19,125
25 May 21	Michael T. Cullen	Common Stock	Grant	Acquire A	No	No	0	4,316	0	216,811
25 May 21	Michael T. Cullen	Stock Option Common Stock	Grant	Acquire A	No	No	4.17	12,368	51.57K	12,368

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

PBLA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: acquisition, Asia, ASPIRE, asset, ASU, back, boast, burden, cadence, colorectal, contemplated, CPP, customary, deteriorate, deterioration, diversification, diversify, entity, Europe, expand, expanded, failure, fall, familial, FAP, FASB, highlighting, Ia, Ib, implement, injected, lack, lead, leading, long, merger, mice, milestone, modulator, neoadjuvant, omicron, opening, ovarian, Pacific, pipeline, post, PR, prolonged, proposed, qualify, ranging, rare, recurrence, removing, retain, retrospective, role, royalty, satisfaction, secure, settlement, shareholder, stage, steady, strategic, Subtopic, sustain, transition, winter, xii, xiii, xiv

Removed: accredited, Additionally, adenocarcinoma, adverse, agent, aggregate, alternate, arising, ASCO, assessment, attend, attendance, begin, begun, blood, CA, care, cell, chain, checkpoint, closed, collaboration, conducting, continued, detachment, disease, disrupt, ductal, Eleven, emerge, epidemic, estimate, exact, exercisable, expenditure, expired, explore, exploring, funding, generated, globe, grow, half, history, impacting, IND, indefinite, inform, informing, ingredient, insurance, interrupted, invest, investigative, investor, June, justify, laboratory, light, listing, mandated, manufacture, Marker, measured, measuring, mechanism, medical, Medicine, Meeting, mitigation, monotherapy, noted, objective, Oncology, ophthalmologic, order, partial, pause, planned, predicted, prevented, procure, reduction, remotely, requested, responding, restarted, resumed, retinal, retinopathy, scheduled, School, screening, sensitizing, separated, shipment, showed, Society, temporary, treat, UFRF, uncertain, valuation, worsen

From filing 10-Q 2022 Q1

Financial reports

View all